Skip to main content
Premium Trial:

Request an Annual Quote

23andMe Laying off 9 Percent of Workforce to Cut Operating Costs

NEW YORK – 23andMe said Friday that it will cut 75 jobs, or about 9 percent of its workforce.

In a filing with the US Securities and Exchange Commission, the consumer genomics and telehealth company disclosed that CEO Anne Wojcicki approved the layoffs on Friday. 23andMe did not indicate what kinds of positions would be eliminated but said that the cuts would be completed during the firm's fiscal first quarter, which ends June 30.

South San Francisco, California-based 23andMe expects the layoffs to reduce annual payroll and benefits expenditures by $12.8 million, according to the filing.

23andMe posted a net loss of $311.7 million in fiscal year 2023, which ended March 31, compared to a net loss of $217.5 million a year earlier. The company expects a net loss of $340 million to $365 million in FY 2024.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.